Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the efficacy and safety of ublituximab in relapsing forms of multiple sclerosis (ULTIMATE 1) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Relapsing Multiple Sclerosis (RMS) | Phase 3 | Status: COMPLETED | Results posted: 2021-12-06